SEC 13F Intelligence

Managers / Q4 2023 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$276M
Q4 2023
Positions
126
Filings on Record
30
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Highvista Strategies LLC reported $276M in U.S.-listed holdings across 126 positions for Q4 2023.

Its largest position, DBC, represents 11.5% of the portfolio.

Compared with Q3 2023, the fund opened 26 new positions and exited 32.

Portfolio Metrics

Turnover
+18.5%
vs prior filed quarter
Top-10 Concentration
+29.5%
share of reported value
Largest Position
+11.5%
Invesco Db Commdy Indx Trck
New / Exited
26 / 32
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.7%ETP: 11.5%ADR: 9.5%Other: 9.0%REIT: 0.4%
  • Common Stock · 69.7% · $192M
  • ETP · 11.5% · $32M
  • ADR · 9.5% · $26M
  • Other · 9.0% · $25M
  • REIT · 0.4% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SYRESPYRE THERAPEUTICS INCNEW+577.6K577.6K+$12M$12M
HESHESS CORPNEW+28.9K28.9K+$4M$4M
SOVOS BRANDS INCNEW+184.6K184.6K+$4M$4M
SP PLUS CORPNEW+78.9K78.9K+$4M$4M
PATHUIPATH INCNEW+123.7K123.7K+$3M$3M
AMBRX BIOPHARMA INCNEW+203.1K203.1K+$3M$3M
37MMRC GLOBAL INCNEW+151.8K151.8K+$2M$2M
KINIKSA PHARMACEUTICALS LTDNEW+88.7K88.7K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DBCINVESCO DB COMMDY INDX TRCKhistory →UNIT11.49%$32M1.44M
2SYRESPYRE THERAPEUTICS INChistory →COM NEW4.51%$12M577.6K
3MSFTMICROSOFT CORPhistory →COM1.97%$5M14.5K
4IMVTIMMUNOVANT INChistory →COM1.85%$5M121.3K
5AXSMAXSOME THERAPEUTICS INChistory →COM1.80%$5M62.3K
6IDYAIDEAYA BIOSCIENCES INChistory →COM1.64%$5M126.8K
7ACIALBERTSONS COS INChistory →COMMON STOCK1.58%$4M188.8K
8VRDNVIRIDIAN THERAPEUTICS INChistory →COM1.57%$4M198.5K
9IMGNEURIMMUNOGEN INChistory →COM1.56%$4M144.8K
10SPLKCHFSPLUNK INChistory →COM1.53%$4M27.6K
11HESHESS CORPhistory →COM1.51%$4M28.9K
12CEREVEL THERAPEUTICS HLDNG ICOM1.50%$4M97.2K
13SOVOS BRANDS INCCOM1.48%$4M184.6K
14SP PLUS CORPCOM1.47%$4M78.9K
15ACLXGBXARCELLX INChistory →COMMON STOCK1.45%$4M72.2K
16NUVLNUVALENT INChistory →COM1.44%$4M54.1K
17CRMSALESFORCE INChistory →COM1.43%$4M15.0K
18IM8NINSMED INChistory →COM PAR $.011.43%$4M126.8K
19CAPRI HOLDINGS LIMITEDSHS1.42%$4M77.7K
20CYMABAY THERAPEUTICS INCCOM1.37%$4M160.3K
21AMEDAMEDISYS INChistory →COM1.35%$4M39.3K
22MERUS N VCOM1.33%$4M133.6K
23MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD1.31%$4M59.8K
24OLMAOLEMA PHARMACEUTICALS INChistory →COM1.26%$3M247.9K
25VVISA INChistory →COM CL A1.16%$3M12.3K
26PATHUIPATH INChistory →CL A1.11%$3M123.7K
27GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS1.11%$3M74.8K
28TXNMPNM RES INChistory →COM1.06%$3M69.9K
29ISIIONIS PHARMACEUTICALS INChistory →COM1.05%$3M57.3K
30AMBRX BIOPHARMA INCCOM1.05%$3M203.1K
31BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.04%$3M158.3K
32IMCRIMMUNOCORE HLDGS PLChistory →ADS1.03%$3M41.6K
33LEGNLEGEND BIOTECH CORPSPONSORED ADS0.97%$3M44.3K
34MAMASTERCARD INCORPORATEDCL A0.94%$3M6.0K
35INDIVIOR PLCORD0.90%$2M164.8K
36METAMETA PLATFORMS INCCL A0.89%$2M6.9K
37XENEXENON PHARMACEUTICALS INCCOM0.87%$2M51.8K
38BKNGBOOKING HOLDINGS INCCOM0.85%$2M657
39XPOXPO INCCOM0.83%$2M26.0K
40X0M1XOMA CORP DELCOM NEW0.80%$2M118.9K
41DVAXDYNAVAX TECHNOLOGIES CORPCOM NEW0.79%$2M156.2K
42GENERAL ELECTRIC COCOM NEW0.79%$2M17.0K
43WCCWESCO INTL INCCOM0.76%$2M12.1K
44FISVFISERV INCCOM0.72%$2M15.0K
45INTUINTUITCOM0.72%$2M3.2K
46TVTXTRAVERE THERAPEUTICS INCCOM0.72%$2M219.4K
47LAURLAUREATE EDUCATION INCCOMMON STOCK0.71%$2M142.5K
48ELVNENLIVEN THERAPEUTICS INCCOM0.69%$2M137.2K
49IMRXIMMUNEERING CORPCLASS A COM0.68%$2M254.5K
50GOOGALPHABET INCCAP STK CL C0.67%$2M13.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • HighVista Private Capital Management LLC

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.